Neutralizing antibodies – a therapeutic option for treating COVID-19 patients
The pandemic brought into sharp focus the need to accelerate the discovery of virus-neutralizing antibodies. While numerous vaccines, which protect against SARS-CoV-2 infections, have been developed in incredibly short timeframes, scientists have also working on creating rapid approaches for developing drugs to protect at-risk populations. Neutralizing monoclonal antibodies, which are already used to treat a variety of conditions, including cancer, autoimmune and inflammatory diseases, are being actively explored as a COVID-19 treatment. However, the standard approach usually takes at least five months as it relies on discovering antibodies from human survivors or immunized animals, and the pandemic has highlighted the urgency to reduce this timeline.